Inscopix and neurotechnology company NeuroNexus have collaborated for the development of an integrated brain electrophysiology and imaging device.

The move seeks to further advance the development of medical devices and new therapies for psychiatric, neurodegenerative and brain trauma disorders. The research will also help in gaining a better understanding of brain function.

According to the agreement, the collaboration will use Inscopix’s imaging expertise, miniaturised microscope-based brain mapping platform as well as multimodal solutions development capabilities.

Meanwhile, NeuroNexus will offer its expertise in miniaturised systems for electrophysiological recording and stimulation.

According to a statement, the neural circuit readouts can be correlated with clinically relevant electrophysiology biomarkers by integrating the two neurotechnology platforms. This will provide new insights to accelerate the development of new drugs.

Inscopix CEO Kunal Ghosh said: “Integration of these platforms will enable completely new insights in how the brain functions in normal state and diseased state, and aid in the discovery and development of novel pharmaceutical drug strategies to combat brain disorders.”

NeuroNexus CEO Daryl Kipke said: “This innovative, multi-modal system will provide a powerful window into brain function over remarkable spatial and temporal scales that will accelerate neuroscience research and development of new clinical neurotechnologies.”

In the future, Inscopix and NeuroNexus intend to offer an early access option, where it will be possible for clinical researchers and scientists to correlate neural circuit dynamics with brain network state.

Inscopix is a brain mapping platform company headquartered in California, US.

In July 2020, Inscopix collaborated with Bruker for its multimodal image registration and analysis (MIRA) platform. The collaboration involved combining the company’s miniature microscope-based nVista and nVoke systems with Bruker’s Ultima multiphoton microscopes.